Navigation Links
Bradmer Medical Isotope Supply For Phase III Trial Secure
Date:12/10/2007

h them for further guidance later this quarter. Following the completion of this meeting, the subsequent update of the regulatory documents, and pending the necessary regulatory approvals, Bradmer will be in a position to initiate the Phase III trial early in 2008.

Bradmer's proposed Phase III trial, evaluating Neuradiab as a treatment for primary glioblastoma multiforme (GBM), is a randomized two arm multi-center study targeting 380 patients in each arm comparing the current standard of care with a group receiving Neuradiab as an adjunct to the current standard of care.

About Bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. MSU engineering team designs innovative medical device
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
7. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
8. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
9. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
10. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ivanCotter Releases Results of Fourth Annual Physi...urvey, DETROIT, July 25 /PRNewswire/ -- Sullivan,...rth annual survey of physician on-call pay rates a...y Report. The survey report,with data from 132 he...ian,on-call pay practices and rates paid for 33 ph...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)... McKesson Corporation Executive, Robert J. Reilly,...re/ -- Aethon Inc.,( http://www.aethon.com ), the ...supply chain logistics, today announced that Rober...President -- Chief Financial Officer., Reilly, wh...ger for,McKesson Corporation,s Specialty Pharmacy ...
(Date:7/25/2008)...STON, July 25 /PRNewswire/ -- The Elekta Family of...er treatment solutions at the 2008,American Associ...ing,demonstrating how the joint forces of Elekta,...on therapy planning and delivery solutions that,st...experience for,patients, as well as enhance clinic...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...yroid hormone plays a major role in the developmen...al levels of the natural hormone can be toxic to a... high levels of thyroid // hormone and still be no... these affected women may carry fetuses that have ...
...ostate cancer is the second-leading cause of cance...ar. The lifetime risk of being diagnosed, one in s... cancer in women. // A new study shows the rate of... velocity, before prostate cancer diagnosis is a m...
...w research shows a significant improvement in trea...led stage I seminoma. Stage I seminoma is typicall...y radiation. Radiation, though, poses a risk of de...n up to 20 years later. Researchers randomized mor...
...tox commonly used for cosmetic purposes to erase t...are using it for medical reasons.//Now, the toxin ...s gastroparesis. Gastroparesis is where there is d... meal. It may be for solid food or for liquids, wh...
Other Medicine News:
(Date:7/23/2008)...ire/ -- Sound Pharmaceuticals (SPI) has filed,an I...or the clinical,testing of a proprietary formulati...nduced hearing loss or ototoxicity. The oral capsu... advanced stage lung cancer,and head and neck canc...,This marks the second development program for SPI...
(Date:7/23/2008)...RNewswire/ -- InCode BioPharmaceutics, Inc.,an em...preclinical test,results demonstrating the utility...ent of the rare chronic blood disorder paroxysmal ...ts will be presented at the XXII,International Com...28,2008., The only treatment currently available...
(Date:7/22/2008)... from a multi-center 293-patient European, trial ...ange Symbol: CYT, MONTREAL, July 22 /PRNewswire-F...bal leader in cryotherapy products to treat cardia...usly presented from three,European study centers u...were published earlier today in the Journal of the...
(Date:7/22/2008)...lity and Efficacy of Treating Patients with ...CISCO, and YONGIN-SI, South Korea, July 22 /PRNews...awa, Ontario), and its South,Korean partner Green ...rom,a Phase I clinical trial of its first-in-class... was well-tolerated and resulted in clear,anti-can...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Standard Glucose Test May Be Wrong One for Obese Children 21873 1Standard Glucose Test May Be Wrong One for Obese Children 21873 2Some patients may not need insulin for long term control of type 2 diabetes 21870 1Some patients may not need insulin for long term control of type 2 diabetes 21870 2UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 1UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 2UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 3A Health Gift for Men on Fathers Day 21866 1A Health Gift for Men on Fathers Day 21866 2
... years; focus moves to,House, WASHINGTON, May 09, ...verwhelmingly passed significant prescription drug...ration more power to deal,with unsafe medicines on...e House, where a strong bill has been introduced b...be congratulated for passing reforms to,ensure pat...
... and a Health Conscious,Public?, WASHINGTON, April...Drug Administration (FDA) must adapt to the most s...ommissioner Andrew von,Eschenbach told attendees a...nference April 12 in Bethesda, Md. , FDA must find...cial and personnel resources to deal with the chal...
Other Medicine Technology:Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 2Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 3Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 4FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut
An easy to use uncomplicated ophthalmoscope.
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame.
Halberg Trial Clips have become a required addition to every refractive stand., ,These useful and inexpensive clips may be fitted over your patient's spectacle frame. Each cell has space for thre
Medicine Products: